Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD85k PE

Anti-Hu CD85k PE

Regulatory status

RUO

Antigen

CD85k

Clone

ZM4.1

Format

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

1P-906-T100

In stock

242.00 USD

Variant

100 tests

1P-906-T100

In stock

242.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody ZM4.1 recognizes an extracellular epitope of human CD85k, a transmembrane glycoprotein expressed by monocytes, macrophages, and dendritic cells.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

human CD85k

Preparation

Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

HM18, ILT3, LIR5, LILRB4

Antigen description

CD85k is a type I transmembrane glycoprotein of ILT/LIR family, and contains three ITIM motives, which recruit protein tyrosine phosphatases SHP-1 and SHP-2, resulting in supression of signal transduction. It is expressed by monocytes, macrophages, and dendritic cells. Antigen presenting cells expressing CD85k and CD85d appear to be crucial to the generation of CD8+ suppressor T cells and CD4+ regulatory T cells.

Entrez Gene ID 11006

UniProt ID Q8NHJ6

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD85k (ZM4.1) PE antibody (10 μl reagent / 100 μl of peripheral whole blood).

Flow cytometry multicolor surface staining pattern of human peripheral blood mononuclear cells stained using anti-human CD123 (6H6) APC antibody (10 μl reagent / 100 μl of peripheral whole blood) and anti-human CD85k (ZM4.1) PE antibody (10 μl reagent / 100 μl of peripheral whole blood).

Separation of human CD123 positive CD85k positive pDC (red-filled) from CD85k negative CD123 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD85k (ZM4.1) PE antibody (10 μl reagent / 100 μl of peripheral whole blood).

Product specific references:

Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Mäurer M, Derfuss T: Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PLoS One 2014 Dec 31;9(12):e115488.
PubMed

Michalski J, Deinzer A, Stich L, Zinser E, Steinkasserer A, Knippertz I: Quercetin induces an immunoregulatory phenotype in maturing human dendritic cells. Immunobiology 2020 Jul;225(4):151929.
PubMed

Littringer K, Moresi C, Rakebrandt N, Zhou X, Schorer M, Dolowschiak T, Kirchner F, Rost F, Keller CW, McHugh D, Leibund G, Landmann S, Robinson MD, Joller N: Common features of regulatory T cell specialization during Th1 responses. Front Immunol. 2018 Jun 13;9:1344.
PubMed

Inui M, Sugahara-Tobinai A, Fujii H, Itoh-Nakadai A, Fukuyama H, Kurosaki T, Ishii T, Harigae H, Takai T: Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE . Int Immunol. 2016 Dec;28(12):597-604.
PubMed

Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R, Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH: Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018 Dec 3;128(12):5647-5662.
PubMed